Scholarlink

<p>Diabetic kidney disease (DKD) remains a serious microvascular consequence of diabetes mellitus globally. DKD pathophysiology is complex and multifactorial; while current therapies are limited, they offer partial renoprotection. However, disease progression continues, underscoring the need for novel therapeutic avenues. Recent advances highlight the “gut-kidney axis” as a pivotal contributor to DKD. Hyperglycemia-induced gut dysbiosis exacerbates renal injury through increased systemic inflammation, RAAS activation, and buildup of uremic toxins. These toxins epigenetically suppress renal expression of α-Klotho,&#xa0;an anti-aging protein with critical antioxidative, anti-inflammatory, and antifibrotic functions, thereby accelerating DKD progression. Despite its emerging importance, α-Klotho remains underexplored as a therapeutic target in DKD, particularly in gut microbiota regulation. α-Klotho could be a potential therapeutic target against DKD via gut-kidney axis modulation. This review elucidates the mechanistic link between gut dysbiosis and the progression of DKD. Additionally, it highlights the impact of uremic toxins on renal α-Klotho expression and subsequent progression to DKD. Therefore, we proposed α-Klotho as a potential therapeutic avenue against DKD through modulation of the gut-kidney axis. This review also highlighted that the combination therapy approach may offer synergistic benefits by targeting multiple pathogenic pathways.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bridging gut microbiota and renal health: Klotho as a promising therapeutic agent in DKD

  • 期刊论文

  • 发表日期：

    2025年12月13日

查看全文
  • Pratik Shankar Rakshe,
  • Anil Bhanudas Gaikwad

摘要

Diabetic kidney disease (DKD) remains a serious microvascular consequence of diabetes mellitus globally. DKD pathophysiology is complex and multifactorial; while current therapies are limited, they offer partial renoprotection. However, disease progression continues, underscoring the need for novel therapeutic avenues. Recent advances highlight the “gut-kidney axis” as a pivotal contributor to DKD. Hyperglycemia-induced gut dysbiosis exacerbates renal injury through increased systemic inflammation, RAAS activation, and buildup of uremic toxins. These toxins epigenetically suppress renal expression of α-Klotho, an anti-aging protein with critical antioxidative, anti-inflammatory, and antifibrotic functions, thereby accelerating DKD progression. Despite its emerging importance, α-Klotho remains underexplored as a therapeutic target in DKD, particularly in gut microbiota regulation. α-Klotho could be a potential therapeutic target against DKD via gut-kidney axis modulation. This review elucidates the mechanistic link between gut dysbiosis and the progression of DKD. Additionally, it highlights the impact of uremic toxins on renal α-Klotho expression and subsequent progression to DKD. Therefore, we proposed α-Klotho as a potential therapeutic avenue against DKD through modulation of the gut-kidney axis. This review also highlighted that the combination therapy approach may offer synergistic benefits by targeting multiple pathogenic pathways.